Drug Profile
ONL 1204
Alternative Names: ONL-1204Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator ONL Therapeutics
- Class Eye disorder therapies; Peptides; Small molecules
- Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; CD95 antigen inhibitors; Fas ligand protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Retinal detachment
- Phase I Dry macular degeneration; Open-angle glaucoma
- Preclinical Retinitis pigmentosa
Most Recent Events
- 29 Feb 2024 ONL Therapeutics completes a phase I trial in Dry age-related macular degeneration in New Zealand and Australia (Intravitreous) (NCT04744662)
- 21 Feb 2024 ONL Therapeutics completes a phase II trial for Retinal detachment in the USA (Intravitreous) (NCT05730218)
- 28 Aug 2023 ONL Therapeutics completes enrolment in phase II trial for Retinal detachment (macula-off rhegmatogenous retinal detachment) in the USA (Intravitreous)